Valeant Outbids Paladin Labs with US$78 M Offer to Acquire Afexa Life Sciences

By Hetather Cartwright

Pharma Deals Review: Vol 2011 Issue 9 (Table of Contents)

Published: 19 Sep-2011

DOI: 10.3833/pdr.v2011.i9.1547     ISSN: 1756-7874

Section: Mergers & Acquisitions



Valeant Pharmaceuticals has outbid rival Paladin Labs with a white knight offer to acquire Afexa Life Sciences, the maker of the Cold-FX® OTC cold and flu brand, for approximately CDN$76 M (US$78 M), which represents a 29% premium to the cash consideration offered under Paladin’s hostile bid...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details